Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast CancerCharlotte Fribbens, Ben O'Leary, Lucy Kilburn, et al.NPJ Breast Cancer|March 2, 2019
ESR1 mutations in metastatic lobular breast cancer patientsChristine Desmedt, Julien Pingitore, Françoise Rothé, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized StudyMassimo Cristofanilli, Hope S Rugo, Seock-Ah Im, et al.Head & Neck|July 14, 2026
Salvage Neck Dissection in Recurrent Head and Neck Squamous Cell Carcinoma After Primary Radiotherapy (RESCUE): An IReC Multicentre Consecutive Cohort StudyAndrew Williamson, Sarah Burton, Zayn Rajan, et al.Oral Oncology|May 28, 2026
Salvage surgery for residual and recurrent head and neck squamous cell carcinoma (RESCUE): An IReC multicentre consecutive cohort studyAndrew Williamson, Sarah Burton, Zayn Rajan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2019
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy ResistanceAlex Pearson, Paula Proszek, Javier Pascual, et al.Clinical Chemistry|August 29, 2018
Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA SequencingSonia Mansukhani, Louise J Barber, Dimitrios Kleftogiannis, et al.Journal of the National Cancer Institute|June 14, 2025
Multidisciplinary evidence-based consensus statements on salvage surgery for recurrent head and neck cancer (International Centre for Recurrent head and neck Cancer)Andrew Williamson, Grainne Brady, Natalie Harris, et al.Biorxiv : the Preprint Server for Biology|September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerAnton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.Nature|March 4, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancerAnton Safonov, Minna Lee, David N Brown, et al.Pageof 3